Vytrus Biotech nine-month 2026 net profit jumps 53% to EUR 3.43 million

Bitget2026/11/05 07:59

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Vytrus Biotech’s unaudited net profit jumped 53% to €3.43 million in the first nine months of 2026.
Sales rose 34% to €8.64 million, while the EBITDA margin reached 56.4%.
New products Toleroxyl and Hydranode expanded the portfolio into recombinant proteins and microbial fermentation, bringing its technology platforms to three.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vytrus Biotech SA published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Vytrus Biotech nine-month 2026 net profit jumps 53% to EUR 3.43 million

You may also like

Crypto prices